Last reviewed · How we verify
TEV-56286
At a glance
| Generic name | TEV-56286 |
|---|---|
| Also known as | emrusolmin, emrusolmin, anle138b, Emrusolmin |
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (PHASE2)
- A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy (PHASE2)
- A Study to Assess New Formulations of TEV-56286 (PHASE1)
- Mass Balance Clinical Trial With TEV-56286 (PHASE1)
- A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TEV-56286 CI brief — competitive landscape report
- TEV-56286 updates RSS · CI watch RSS
- Teva Branded Pharmaceutical Products R&D, Inc. portfolio CI